News

Daiichi Sankyo oncology research and development global head and executive vice president Dr Antoine Yver said: “With a successful track record and our first bispecific antibody incorporating the

Indivior PLC and its U.S. subsidiary, Indivior Inc., marketers and distributors of SUBOXONE, joined partner Aquestive in the settlement with Par Pharmaceuticals, Inc., an operating company of Endo

AurKa Pharma was established as part of the TVM Life Science Ventures VII fund, to develop an Aurora kinase A inhibitor called AK-01. The oncology compound was discovered originally

The study has failed to achieve statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca is continuing the Terranova trial, which is also a

Under the development agreement, Hemogenyx will receive on a cost-free basis technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property which

RXi Pharmaceuticals president and CEO Geert Cauwenbergh said: "Iovance is the leading company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. Our agreement will allow Iovance

In 2010, the oral disease-modifying therapy (DMT) was approved by the US Food and Drug Administration (FDA) for the treatment of RMS for patients aged 18 years and

Amryt estimates there may be up to 450 additional patients who could benefit from treatment with Lojuxta across the countries covered by the extended agreement, representing an increase

The committee’s non-binding recommendation will be considered by the FDA in its review of Akcea’s New Drug Application for WAYLIVRA.  The PDUFA date for completion of the review